Skip to main content
Clinical Trials/NCT01511770
NCT01511770
Completed
Phase 1

Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Fluconazole Tablets 200 mg and PFIZER (DIFLUCAN) 200 MG in Healthy Males Under Fasting Condition.

Dr. Reddy's Laboratories Limited1 site in 1 country17 target enrollmentAugust 2002
ConditionsHealthy
InterventionsFluconazole

Overview

Phase
Phase 1
Intervention
Fluconazole
Conditions
Healthy
Sponsor
Dr. Reddy's Laboratories Limited
Enrollment
17
Locations
1
Primary Endpoint
Area Under Curve (AUC)
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The objective of this study was an open-label, randomized, 2-way crossover to compare the single-dose relative bioavailability of Dr. Reddy's Laboratories, Ltd. and Pfizer (Diflucan®) 200 mg fluconazole tablets under fasting conditions.

Detailed Description

Detailed Description : The study was conducted as an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 18 healthy adult male volunteers. A total of 17 subjects completed the clinical phase of the study. In each period, subjects were housed from the morning dosing until after the 72-hour blood draw. Single oral 200 mg doses were separated by a washout period of 21 days.

Registry
clinicaltrials.gov
Start Date
August 2002
End Date
September 2002
Last Updated
14 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • History or presence of significant:
  • cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.
  • In addition, history or presence of:
  • alcoholism or drug abuse within the past year;
  • hypersensitivity or idiosyncratic reaction to fluconazole or other azoles. Subjects who have used any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days prior to first dose.
  • Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 28 days prior to first dose.
  • Subjects who have been on an abnormal diet (for whatever reason) during the 28 days prior to the first dosing.
  • Subjects who, through completion of the study, would have donated in excess of:
  • 500 mL of blood in 14 days, or
  • 500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator),

Arms & Interventions

Fluconazole

Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.

Intervention: Fluconazole

Diflucan

Diflucan 200 mg fluconazole tablets of Pfizer

Intervention: Fluconazole

Outcomes

Primary Outcomes

Area Under Curve (AUC)

Time Frame: pre dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5,4, 6, 9, 12, 24, 48 and 72 hours post-dose.

Study Sites (1)

Loading locations...

Similar Trials